14 CLINICAL STUDIES The STRIVERDI RESPIMAT clinical development program included three dose-ranging trials in COPD patients, four dose-ranging trials in asthma patients, and eight confirmatory trials in patients with COPD.
14 CLINICAL STUDIESThe STRIVERDI RESPIMAT clinical development program included three dose-ranging trials in COPD patients, four dose-rangingtrials in asthma patients, and eight confirmatory trials in patients with COPD.